Cg Oncology Inc’s recent filing unveils that its Director POST LEONARD E unloaded Company’s shares for reported $41430.0 on Nov 17 ’25. In the deal valued at $41.43 per share,1,000 shares were sold. As a result of this transaction, POST LEONARD E now holds 0 shares worth roughly $0.0.
Then, POST LEONARD E sold 1,000 shares, generating $43,250 in total proceeds. Upon selling the shares at $43.25, the Director now owns 0 shares.
Before that, Mulay James sold 5,903 shares. Cg Oncology Inc shares valued at $259,673 were divested by the Director at a price of $43.99 per share. As a result of the transaction, Mulay James now holds 0 shares, worth roughly $0.0.
Truist initiated its Cg Oncology Inc [CGON] rating to a Buy in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early October with a ‘”a Buy”‘ rating. Piper Sandler began covering CGON with “an Overweight” recommendation on August 19, 2025.
Price Performance Review of CGON
On Monday, Cg Oncology Inc [NASDAQ:CGON] saw its stock fall -3.55% to $43.25. Over the last five days, the stock has gained 1.91%. Cg Oncology Inc shares have risen nearly 27.58% since the year began. Nevertheless, the stocks have risen 50.80% over the past one year. While a 52-week high of $45.94 was reached on 11/28/25, a 52-week low of $14.80 was recorded on 04/09/25.
Levels Of Support And Resistance For CGON Stock
The 24-hour chart illustrates a support level at 42.50, which if violated will result in even more drops to 41.75. On the upside, there is a resistance level at 44.64. A further resistance level may holdings at 46.02.
How much short interest is there in Cg Oncology Inc?
A steep rise in short interest was recorded in Cg Oncology Inc stocks on 2025-11-14, growing by 0.98 million shares to a total of 13.21 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 12.22 million shares. There was a rise of 7.44%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 02, 2025 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $41 price target.
